Aminopeptidases of Malaria Parasites: New Targets for Chemotherapy

Author(s): Katharine R. Trenholme, Christopher L. Brown, Tina S. Skinner-Adams, Colin Stack, Jonathan Lowther, Joyce To, Mark W. Robinson, Sheila M. Donnelly, John P. Dalton, Donald L. Gardiner

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Volume 10 , Issue 3 , 2010


Become EABM
Become Reviewer
Call for Editor

Abstract:

Novel targets for new drug development are urgently required to combat malaria, a disease that puts half of the worlds population at risk. One group of enzymes identified within the genome of the most lethal of the causative agents of malaria, Plasmodium falciparum, that may have the potential to become new targets for antimalarial drug development are the aminopeptidases. These enzymes catalyse the cleavage of the N-terminal amino acids from proteins and peptides. P. falciparum appears to encode for at least nine aminopeptidases, two neutral aminopeptidases, one aspartyl aminopeptidase, one aminopeptidase P, one prolyl aminopeptidase and four methionine aminopeptidases. Recent advances in our understanding of these genes and their protein products are outlined in this review, including their potential for antimalarial drug development.

Keywords: Plasmodium falciparum, malaria, aminopeptidase, drug discovery

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 3
Year: 2010
Page: [217 - 225]
Pages: 9
DOI: 10.2174/187152610791163363
Price: $65

Article Metrics

PDF: 39